Search results for "" 2279 results found

• IP Cases & Articles

  Generics UK (Mylan) v Novartis: EWHC 2403 Rivastigmine

  Posted on 21 October 2011
  The High Court has recently handed down judgment resulting in the revocation of the Novartis patent and SPC relating to rivastigmine (Exelon®). This is a further action where the Court was faced with a patent relating to the resolved enantiomer of a prior art racemic compound. Unlike the previous occasions,…
• IP Cases & Articles

  CJEU Stem Cell Patents: Br��stle v Greenpeace (C-34/10)

  Posted on 18 October 2011
  The Court of Justice of the European Union (CJEU) today issued its decision in Brüstle v Greenpeace (C-34/10) which relates to the patentability of technology based on the use of human embryonic stem cells (hESC).
• IP Cases & Articles

  MedImmune v Novartis: Obviousness and Lack of Priority��

  Posted on 03 October 2011
  The judgment by Mr Justice Arnold runs to 161 pages, and relates to a large family of patents jointly owned by MedImmune and MRC, which were directed to antibody phage display technology. Allegedly these patents were infringed by Novartis’ sale of Lucentis (chemically named ranibizumab), which is a treatment for…
• Newsletter

  Patent Newsletter No.25

  Posted on 01 October 2011
• IP Cases & Articles

  Interflora v Marks & Spencer: Online Keywords Dispute

  Posted on 23 September 2011
  Marks & Spencer had previously made use of Google’s Adwords facility to select the name ‘Interflora’ (in a variety of spellings) to promote its own retail flower services. When a Google user typed ‘Interflora’ into its search engine, an advertisement for the services provided by Marks & Spencer was displayed…
• IP Cases & Articles

  Patenting Genes and Diagnostics

  Posted on 11 September 2011
  This article was originally published by Life Sciences Intellectual Property Review.
  

  Simon O'Brien

  Partner, Patent Attorney
• Newsletter

  Trade Mark Newsletter No.58

  Posted on 01 September 2011
• IP Cases & Articles

  Myriad: Association for Molecular Pathology

  Posted on 09 August 2011
  On 29 July 2011, the Federal Circuit issued its much anticipated decision on the ‘Myriad case’. The court held that that claims directed to isolated DNA were patent eligible but diagnostic claims that relate to ‘comparing’ or ‘analysing’ sequences were patent ineligible.
  

  Simon O'Brien

  Partner, Patent Attorney
• Newsletter

  Patent Newsletter No.24

  Posted on 01 August 2011
• IP Cases & Articles

  Surgical Methods G1/07 ��� Tech Board of Appeal T0663/02

  Posted on 19 July 2011
  What is a 'surgical method'? In the wake of Enlarged Board of Appeal (EBA) decision G1/07 which supposedly provided clarity on this point, many patent attorneys have had sleepless nights when formulating claims which require a step of 'injecting' a compound into a subject.

Page 214 of 228